+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • ID: 5480782
  • Report
  • September 2021
  • Region: Global
  • 199 Pages
  • Allied Analytics LLP
UP TO OFF until May 20th 2022

The global enteral collagen peptide protein market was valued at $14,586 thousand in 2020, and is projected to reach $25,811 thousand by 2030, registering a CAGR of 7.2% from 2021-2030.



Collagen peptide protein is a protein derived from animal collagen. Collagen peptides are a versatile source of protein and an important element of healthy nutrition. Their nutritional and physiological properties promote the health of bones & joints and prevent osteoarthritis.

Enteral collagen peptide protein is a rich source of healthy nutrients that is prescribed to patients, who are unable to consume sufficient nutrients orally but whose gastrointestinal function help in digestion and absorption. Enteral collagen peptide protein products are used when a patient is unable to eat due to some illness, has swallowing difficulties, or has undergone surgery that may interfere with the normal eating process. In this process, collagen peptides protein are administered directly into the stomach, duodenum, or jejunum of a patient via enteral pumps and enteral feeding tubes. Enteral collagen peptide protein supplements are prescribed to patients suffering from chronic diseases such as malnutrition, osteoarthritis, and osteoporosis. Generally, collagen peptides protein enteral feeding is used in hospitals & clinics, home care, and nursing homes.

The growth of the global enteral collagen peptide protein market is majorly driven by the rising in the prevalence of chronic illnesses such as osteoarthritis and cardiovascular diseases and an increase in the application of enteral collagen peptide proteins in the healthcare sector. Furthermore, surge in the geriatric population and favorable government initiatives to promote a healthy diet among the population. However, poor demand and lack of awareness of enteral collagen peptide protein products in underdeveloped countries hamper the market growth. Conversely, high growth potential in untapped emerging economies is expected to provide lucrative opportunities for the growth of the global market.

The global enteral collagen peptide protein market is segmented into form, age group, end user, and region. On the basis of form, the market is bifurcated into powder and liquid. By age group, it is segregated into adults (above 18) and pediatrics (below 18). Depending on end user, it is fragmented into hospitals & clinics, homecare, and nursing home. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global enteral collagen peptide protein market include Abbott Laboratories, Danone S.A (Nutricia). Dermarites Industries LLC, Medtronic, Inc, Medlin Industries, Inc, Global Health Products, Inc., OP2 labs, LLC, Fresenius Kabi AG, Gelita AG, and Weishardt Holding SA


KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Form

  • Powder
  • Liquid

By Age-Group

  • Adults (Above 18)
  • Pediatrics (Below 18)

By End User

  • Hospitals & clinics
  • Homecare
  • Nursing Home

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Players

  • Abbott laboratories
  • Danone S.A (Nutricia)
  • Dermarites Industries LLC
  • Medtronic, Inc
  • Medline Industries, Inc
  • Global Health Products, Inc.
  • OP2 labs, LLC
  • Fresenius Kabi AG
  • Gelita AG
  • Weishardt Holding SA
Frequently Asked Questions about the Global Enteral Collagen Peptide Protein Market

What is the estimated value of the Global Enteral Collagen Peptide Protein Market?

The Global Enteral Collagen Peptide Protein Market was estimated to be valued at $14586.0 thousand in 2020.

What is the growth rate of the Global Enteral Collagen Peptide Protein Market?

The growth rate of the Global Enteral Collagen Peptide Protein Market is 5.9%, with an estimated value of $25811.0 thousand by 2030.

What is the forecasted size of the Global Enteral Collagen Peptide Protein Market?

The Global Enteral Collagen Peptide Protein Market is estimated to be worth $25811.0 thousand by 2030.
Note: Product cover images may vary from those shown

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market share analysis, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of chronic disorders
3.5.1.2. Surge in geriatric population
3.5.1.3. Rise in number of malnutrition cases
3.5.2. Restraint
3.5.2.1. Poor demand in underdeveloped countries
3.5.3. Opportunity
3.5.3.1. High growth potential in emerging markets
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on enteral collagen peptide protein market
CHAPTER 4: ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM
4.1. Overview
4.1.1. Market size and forecast
4.2. Powder
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Liquid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
CHAPTER 5: ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market size and forecast
5.2. Adults (above18)
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Pediatric (below 18 years)
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
CHAPTER 6: ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals & clinics
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Homecare
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Nursing home
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by form
7.2.4. Market size and forecast, by age group
7.2.5. Market size and forecast, by end user
7.2.6. U. S.
7.2.6.1. U. S. market size and forecast, by form
7.2.6.2. U. S. market size and forecast, by age group
7.2.6.3. U. S. market size and forecast, by end user
7.2.7. Canada
7.2.7.1. Canada market size and forecast, by Form
7.2.7.2. Canada market size and forecast, by age group
7.2.7.3. Canada market size and forecast, by end user
7.2.8. Mexico
7.2.8.1. Mexico market size and forecast, by form
7.2.8.2. Mexico market size and forecast, by age group
7.2.8.3. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by form
7.3.4. Market size and forecast, by age group
7.3.5. Market size and forecast, by end user
7.3.6. Germany
7.3.6.1. Germany market size and forecast, by form
7.3.6.2. Germany market size and forecast, by age group
7.3.6.3. Germany market size and forecast, by end user
7.3.7. France
7.3.7.1. France market size and forecast, by form
7.3.7.2. France market size and forecast, by age group
7.3.7.3. France market size and forecast, by end user
7.3.8. UK
7.3.8.1. UK market size and forecast, by form
7.3.8.2. UK market size and forecast, by age group
7.3.8.3. UK market size and forecast, by end user
7.3.9. Italy
7.3.9.1. Italy market size and forecast, by form
7.3.9.2. Italy market size and forecast, by age group
7.3.9.3. Italy market size and forecast, by end user
7.3.10. Spain
7.3.10.1. Spain market size and forecast, by form
7.3.10.2. Spain market size and forecast, by age group
7.3.10.3. Spain market size and forecast, by end user
7.3.11. Rest of Europe
7.3.11.1. Rest of Europe market size and forecast, by form
7.3.11.2. Rest of Europe market size and forecast, by age group
7.3.11.3. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by form
7.4.4. Market size and forecast, by age group
7.4.5. Market size and forecast, by end user
7.4.6. Japan
7.4.6.1. Japan market size and forecast, by form
7.4.6.2. Japan market size and forecast, by age group
7.4.6.3. Japan market size and forecast, by end user
7.4.7. China
7.4.7.1. China market size and forecast, by form
7.4.7.2. China market size and forecast, by age group
7.4.7.3. China market size and forecast, by end user
7.4.8. Australia
7.4.8.1. Australia market size and forecast, by form
7.4.8.2. Australia market size and forecast, by age group
7.4.8.3. Australia market size and forecast, by end user
7.4.9. India
7.4.9.1. India market size and forecast, by form
7.4.9.2. India market size and forecast, by age group
7.4.9.3. India market size and forecast, by end user
7.4.10. South Korea
7.4.10.1. South Korea market size and forecast, by form
7.4.10.2. South Korea market size and forecast, by age group
7.4.10.3. South Korea market size and forecast, by end user
7.4.11. Rest of Asia-Pacific
7.4.11.1. Rest of Asia-Pacific market size and forecast, by form
7.4.11.2. Rest of Asia-Pacific market size and forecast, by age group
7.4.11.3. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by form
7.5.4. Market size and forecast, by age group
7.5.5. Market size and forecast, by end user
7.5.6. Brazil
7.5.6.1. Brazil market size and forecast, by form
7.5.6.2. Brazil market size and forecast, by age group
7.5.6.3. Brazil market size and forecast, by end user
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia market size and forecast, by form
7.5.7.2. Saudi Arabia market size and forecast, by age group
7.5.7.3. Saudi Arabia market size and forecast, by end user
7.5.8. South Africa
7.5.8.1. South Africa market size and forecast, by form
7.5.8.2. South Africa market size and forecast, by age group
7.5.8.3. South Africa market size and forecast, by end user
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA market size and forecast, by form
7.5.9.2. Rest of LAMEA market size and forecast, by age group
7.5.9.3. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. DANONE S. A. (NUTRICIA)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. DERMARITE INDUSTRIES LLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. FRESENIUS KABI AG
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. GLOBAL HEALTH PRODUCTS, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MEDLINE INDUSTRIES, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. MEDTRITION INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. OP2 LABS LLC
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.9. GELITA AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. WEISHARDT HOLDING SA
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
List of Tables
TABLE 01. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 02. POWDER ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020-2030 ($THOUSAND)
TABLE 03. LIQUID ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020-2030 ($THOUSAND)
TABLE 04. GLOBAL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 05. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR ADULTS (ABOVE18), BY REGION, 2020-2030 ($THOUSAND)
TABLE 06. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR PEDIATRIC (BELOW 18 YEARS), BY REGION, 2020-2030 ($THOUSAND)
TABLE 07. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 08. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOSPITAL & CLINICS, BY REGION, 2020-2030 ($THOUSAND)
TABLE 09. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOMECARE, BY REGION, 2020-2030 ($THOUSAND)
TABLE 10. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR NURSING HOMES, BY REGION, 2020-2030 ($THOUSAND)
TABLE 11. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020-2030 ($THOUSAND)
TABLE 12. NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 13. NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 14. NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 15. NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 16. U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 17. U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 18. U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 19. CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 20. CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 21. CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 22. MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($MILLION)
TABLE 23. MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 24. MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 25. EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 26. EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 27. EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 28. EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 29. GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($MILLION)
TABLE 30. GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 31. GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 32. FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 33. FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 34. FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 35. UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 36. UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 37. UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 38. ITALY ENTERAL COLLAGEN PEPTIDEP ROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 39. ITALY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 40. ITALY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 41. SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 42. SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 43. SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 44. REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 45. REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 46. REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 47. ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 48. ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 49. ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2039 ($THOUSAND)
TABLE 50. ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 51. JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 52. JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 53. JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 54. CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 55. CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 56. CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 57. AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 58. AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 59. AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 60. INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 61. INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 62. INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 63. SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 64. SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 65. SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 66. REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 67. REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 68. REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 69. LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 70. LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 71. LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 72. LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 73. BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 74. BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 75. BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 76. SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 77. SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 78. SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 79. SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020-2030 ($THOUSAND)
TABLE 80. SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 81. SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 82. REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020-2030 ($THOUSAND)
TABLE 83. REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020-2030 ($THOUSAND)
TABLE 84. REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020-2030 ($THOUSAND)
TABLE 85. ABBOTT: COMPANY SNAPSHOT
TABLE 86. ABBOTT: OPERATING SEGMENTS
TABLE 87. ABBOTT: PRODUCT PORTFOLIO
TABLE 88. DANONE: COMPANY SNAPSHOT
TABLE 89. DANONE: OPERATING SEGMENTS
TABLE 90. DANONE: PRODUCT PORTFOLIO
TABLE 91. DERMARITE: COMPANY SNAPSHOT
TABLE 92. DERMARITE: OERATING SEGMENT
TABLE 93. DERMARITE: PRODUCT PORTFOLIO
TABLE 94. FRESENIUS KABI AG: COMPANY SNAPSHOT
TABLE 95. FRESENIUS KABI AG: OPERATING SEGMENTS
TABLE 96. FRESENIUS KABI AG: PRODUCT PORTFOLIO
TABLE 97. GLOBAL HEALTH: COMPANY SNAPSHOT
TABLE 98. GLOBAL HEALTH: OPERATING SEGMENTS
TABLE 99. GLOBAL HEALTH: PRODUCT PORTFOLIO
TABLE 100. MEDLINE: COMPANY SNAPSHOT
TABLE 101. MEDLINE: OPERATING SEGMENTS
TABLE 102. MEDLINE: PRODUCT PORTFOLIO
TABLE 103. MEDTRITION: COMPANY SNAPSHOT
TABLE 104. MEDTRITION: OPERATING SEGMENTS
TABLE 105. MEDTRITION: PRODUCT PORTFOLIO
TABLE 106. OP2 LABS: COMPANY SNAPSHOT
TABLE 107. OP2 LABS: OERATING SEGMENT
TABLE 108. OP2 LABS: PRODUCT PORTFOLIO
TABLE 109. GELITA: COMPANY SNAPSHOT
TABLE 110. GELITA: OPERATING SEGMENTS
TABLE 111. GELITA: PRODUCT PORTFOLIO
TABLE 112. WEISHARDT: COMPANY SNAPSHOT
TABLE 113. WEISHARDT: OERATING SEGMENT
TABLE 114. WEISHARDT: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. MODERATE THREAT OF SUBSTITUTION
FIGURE 07. MODERATE COMPETITIVE RIVALRY
FIGURE 08. TOP PLAYER POSITIONING, 2020
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE SAHRE ANALYSIS OF POWDER ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11. COMPARATIVE SAHRE ANALYSIS OF LIQUID ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE SAHRE ANALYSIS OF ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR ADULTS (ABOVE18), BY COUNTRY, 2020 & 2030 (%)
FIGURE 13. COMPARATIVE SAHRE ANALYSIS OF ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR PEDIATRIC (BELOW 18 YEARS), BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SAHRE ANALYSIS OF ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOSPITAL & CLINICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE SAHRE ANALYSIS OF ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOMECARE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE SAHRE ANALYSIS OF ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR NURSING HOMES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 18. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 19. ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 20. DANONE: NET SALES, 2018-2020 ($MILLION)
FIGURE 21. DANONE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 22. DANONE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 23. FRESENIUS KABI AG: REVENUE, 2018-2020 ($MILLION)
FIGURE 24. FRESENIUS KABI AG: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25. FRESENIUS KABI AG: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26. GELITA: NET SALES, 2018-2020 ($MILLION)
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...